Cognitive decline and T2DM T2DM - A disconnect in the evidence?

Nature Reviews Endocrinology

Volumn 10, Issue 5, 2014, Pages 258-260

  Strachan, Mark W J ^a   Price, Jacqueline F ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ANTIDIABETIC AGENT;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN SIZE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COGNITION; DEMENTIA; DISEASE COURSE; DYSLIPIDEMIA; EXECUTIVE FUNCTION; FACTORIAL DESIGN; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; MENTAL DETERIORATION; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; VERBAL MEMORY; AGED; ARTICLE; COGNITIVE DEFECT; FEMALE; INTERVENTION STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PSYCHOLOGICAL ASPECT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INTERVENTION STUDIES; MALE; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC;

EID: 84899490708     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.38     Document Type: Note

References (10)

1. Strachan, M. W. J., Reynolds, R. M., Marioni, R. E. & Price J. F. Cognitive function, dementia and diabetes in the elderly. Nat. Rev. Endocrinol. 7, 108-114 (2011).
2. Ritchie, K. et al. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 341, c3885 (2010).
3. Kloppenburg, R. P., van den Berg, E., Kappelle, L. J. & Biessels, G. J. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur. J. Pharmacol. 585, 97-108 (2008).
4. Launer, L. J. et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomized open-label substudy. Lancet Neurol. 10, 969-977 (2011).
5. Williamson, J. D. et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels. A randomized clinical trial. JAMA Intern. Med. 174, 324-333 (2014).
6. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
7. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2011).
8. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2011).
9. McGuinness, B., Todd, S., Passmore, P. & Bullock, R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews Issue 4. Art. No.: CD004034. http://dx.doi.org/10.1002/14651858.CD004034.pub3.
10. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD003160. http://dx.doi.org/10.1002/14651858.CD003160.pub2.